3 months on fin/min/derma stamp. 2.5 weeks of hair growth in both pictures
    Progress Pictures 8/26/2024

    From the encyclopedia
    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Finasteride (oral) 1 mg 1x daily 3 months
    💧 Minoxidil (topical) 2x daily 3 months
    💧 Derma stamp (topical) 1 mm 1-2x weekly 3 months
    the tone is 😀 positive with impressive results.

    Other terms

    A user shared progress pictures after 3 months of using finasteride, minoxidil, and a derma stamp, showing 2.5 weeks of hair growth. They reported no side effects and take 1 mg of finasteride daily.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results

      research Experimental and early investigational drugs for androgenetic alopecia

      11 citations , July 2017 in “Expert Opinion on Investigational Drugs”
      This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

      research Drug discovery for alopecia: gone today, hair tomorrow

      70 citations , February 2015 in “Expert Opinion on Drug Discovery”
      This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.

      research Male androgenetic alopecia

      54 citations , July 2002 in “Clinical and Experimental Dermatology”
      This article provides a critical overview of recent discoveries in the genetics and molecular processes involved in androgenetic alopecia, focusing on its polygenic basis and DHT dependency, but reports no new clinical results.